OPEN ACCESS

ORIGINAL RESEARCH

Blood functional assay for rapid clinical interpretation of germline *TP53* variants

Sabine Raad,¹ Marion Rolain,¹ Sophie Coutant,¹ Céline Derambure,¹ Raphael Lanos,¹ Françoise Charbonnier,¹ Jacqueline Bou,¹ Emilie Bouvignies,¹ Gwendoline Lienard,¹ Stéphanie Vasseur,¹ Michael Farrell,² Olivier Ingster,³ Stéphanie Baert Desurmont,¹ Edwige Kasper,¹ Gaëlle Bougeard,¹ Thierry Frébourg,¹ Isabelle Tournier ¹

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jmedgenet-2020-107059>).

¹Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics, F76000, Normandy Centre for Genomic and Personalized Medicine, University of Rouen Faculty of Medicine and Pharmacy, Rouen, France

²Cancer Genetics Service, Mater Private Hospital, Dublin, Leinster, Ireland

³Department of Genetics, University Hospital Centre Angers, Angers, Pays de la Loire, France

Correspondence to

Professor Thierry Frébourg, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics, F76000, Normandy Centre for Genomic and Personalized Medicine, University of Rouen Faculty of Medicine and Pharmacy, Rouen 76183, France; thierry.frebourg@chu-rouen.fr

SR and MR contributed equally.

Received 1 April 2020

Revised 5 August 2020

Accepted 1 September 2020

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Raad S, Rolain M, Coutant S, et al. *J Med Genet* Epub ahead of print: [please include Day Month Year]. doi:10.1136/jmedgenet-2020-107059

ABSTRACT

Background The interpretation of germline *TP53* variants is critical to ensure appropriate medical management of patients with cancer and follow-up of variant carriers. This interpretation remains complex and is becoming a growing challenge considering the exponential increase in *TP53* tests. We developed a functional assay directly performed on patients' blood.

Methods Peripheral blood mononuclear cells were cultured, activated, exposed to doxorubicin and the p53-mediated transcriptional response was quantified using reverse transcription–multiplex ligation probe amplification and RT-QMPSF assays, including 10 p53 targets selected from transcriptome analysis, and two amplicons to measure p53 mRNA levels. We applied this blood functional assay to 77 patients addressed for *TP53* analysis.

Results In 51 wild-type *TP53* individuals, the mean p53 functionality score was 12.7 (range 7.5–22.8). Among eight individuals harbouring likely pathogenic or pathogenic variants, the scores were reduced (mean 4.8, range 3.1–7.1), and p53 mRNA levels were reduced in patients harbouring truncating variants. We tested 14 rare unclassified variants (p.(Pro72His), p.(Gly105Asp), p.(Arg110His), p.(Phe134Leu), p.(Arg158Cys), p.(Pro191Arg), p.(Pro278Arg), p.(Arg283Cys), p.(Leu348Ser), p.(Asp352Tyr), p.(Gly108_Phe109delinsVal), p.(Asn131del), p.(Leu265del), c.-117G>T) and 12 yielded functionally abnormal scores. Remarkably, the assay revealed that the c.*1175A>C polymorphic variant within *TP53* poly-adenylation site can impact p53 function with the same magnitude as a null variant, when present on both alleles, and may act as a modifying factor in pathogenic variant carriers.

Conclusion This blood p53 assay should therefore be a useful tool for the rapid clinical classification of germline *TP53* variants and detection of non-coding functional variants.

INTRODUCTION

Identification of a germline pathogenic *TP53* (MIM: *191170) variant in a patient with cancer has drastic medical impacts.¹ Indeed, in *TP53* variant carriers, chemotherapy and radiotherapy have been shown to contribute to the development of subsequent primary cancers, the incidence of which is remarkably high (above 40%).^{1–4} Therefore, in these patients, surgical treatment should

be prioritised and radiotherapy and chemotherapy avoided, if possible, or at least carefully discussed in terms of benefit:risk ratio between risk of recurrence and risk of inducing second primary tumours. Furthermore, *TP53* variant carriers should have specific surveillance protocols, including annual whole-body MRI,^{5–6} whose efficiency for early tumour detection has recently been shown by numerous studies.^{5–14}

Interpretation of germline *TP53* variants, which are mainly missense variants, remains particularly complex. Whereas germline variants of *TP53* were initially detected in Li-Fraumeni syndrome (LFS, MIM#151623),^{15–17} our perception of cancers related to germline alterations of *TP53* has drastically evolved over time.^{1–2–18–19} The presence of a disease-causing germline variant should be considered in patients fulfilling Chompret criteria, which were sequentially updated and extended.¹ The question of germline *TP53* variant interpretation is becoming a growing concern in the field because the *TP53* gene is currently included in many cancer gene panels, and the number of *TP53* tests performed in patients not fulfilling the criteria mentioned earlier has increased exponentially.^{20–21}

Classification of *TP53* variants, in agreement with the American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines, is based on several items, including frequency of the variant in the general population (gnomAD; <https://gnomad.broadinstitute.org/>), segregation data, bioinformatics predictions and functional assays developed in yeast or human cancer cell lines.²² One of the first assays commonly used for *TP53* missense variant interpretation was developed in yeast and is based on the expression of *TP53* cDNA in strains containing reporter plasmids with different p53 binding sites.²³ In this assay, p53 variants are classified as functional, not functional or partially functional if the transcriptional activity is conserved for some but not all yeast reporter plasmids (<http://p53.iarc.fr/>). More recently, two teams have developed in human cancer cell lines high throughput p53 functional assays.^{24–25} Kotler *et al*²⁴ generated a synthetic library of *TP53* variants located within the p53 DNA-binding domain and quantified the antiproliferative activity of these variants in the p53-null H1299 cancer cell line. In this assay,

TP53 variants are categorised as ‘wild-type *TP53*-like variant’ (functional) or ‘disrupting’ (non-functional). In another assay, Giacomelli *et al*²⁵ generated by saturation mutagenesis a *TP53* library and tested the ability of the variants (1) to restore the survival of the p53-null A459 cell line exposed to high doses of DNA damaging agents, in order to detect loss of function (LOF) variants and (2) to induce in p53-wild-type A459 cells resistance to Nutlin-3, in order to detect variants with dominant negative effect (DNE).

We previously developed, in Epstein-Barr virus-immortalised lymphocytes, a p53 functional assay exploring the transcriptional activity of the protein underlying its tumour suppressor activity.²⁶ This assay is based on the exposure of cells to DNA damaging agents followed by the measurement of the p53 transcriptional response.^{27–28} With this assay, we showed that pathogenic *TP53* variant carriers exhibit a constitutive defect in the transcriptional response to DNA damage, establishing a biological endophenotype associated with germline pathogenic variants.^{27–28} Compared with the other assays, its main advantage is to evaluate the impact of heterozygous variants in the genetic context of the patients. Its main disadvantage is that it requires EBV immortalisation, which is time-consuming and, therefore, not suited for a rapid classification and interpretation of *TP53* variants in medical practice.

Therefore, despite the different tools indicated previously and before the completion in the future of curated international databases, interpretation of germline *TP53* variants remains challenging in clinical practice. This prompted us to develop a p53 functional assay derived from the previous one but performed on fresh blood samples and suitable for rapid interpretation and medical management of patients. We show here that this assay can accurately detect pathogenic variants and can be used to reallocate unclassified variants by integrating the results to the classification strategy.²² Furthermore, this assay revealed that a *TP53* polymorphism (rs78378222), present in 1.7% of the European population, compromises p53 functional activity with the same magnitude as a heterozygous null variant, when carried on both alleles.

METHODS

Cell culture and treatment

EBV-immortalised cell lines were maintained in RPMI 1640 medium (GIBCO; Life Technologies, Carlsbad, California, USA) with 10% fetal calf serum (Invitrogen, Life Technologies) and 1% L-glutamine (Invitrogen) at 37°C with 5% CO₂. Cells were seeded in duplicate in 12-well plates (Corning, New York, USA) at a density of 10⁶ cells/well. Cells were treated or not with 200 ng/mL (0.3 μM final concentration) of doxorubicin (Sigma Aldrich, St. Louis, Missouri, USA) for 8 hours. Cells were washed with 1× PBS and harvested for RNA extraction.

Peripheral blood mononuclear cell (PBMC) isolation and culture

Blood samples were collected in EDTA tubes and kept for 2 days at room temperature before PBMC isolation on a lymphocyte separation medium (Eurobio, Evry, France). From 2.5 to 10.0 mL of blood per patient was used for PBMC isolation. Cell number and cell viability were assessed on a NanoEnTek Adam automatic cell counter with the AccuChip Kit (ScienceTEC, Villebon-sur-Yvette, France). One million cells were seeded per well in a 24-well plate and were let to grow for 48 hours in a lymphocyte activating medium (Chromosome Medium P, AmpliTech,

Compiègne, France). At least two wells were seeded per patient (treated and untreated) and duplicates or triplicates were performed whenever possible. Cells were treated with 800 ng/mL of doxorubicin for 8 hours, washed with 1× PBS, harvested and RNA extraction was performed using the NucleoSpin RNA XS kit (Macherey Nagel, Düren, Germany) according to the manufacturer's instructions and quantified using a UV-VIS ND-1000 spectrophotometer (Biocompare, Nanodrop Technologies, USA).

RNA-Seq

Four control EBV cell lines wild-type for *TP53* and four heterozygous *TP53*-mutant cell lines, corresponding to three canonical dominant negative missense variants (p.(Arg175His), p.(Arg248Trp) and p.(Arg273His)) and one complete deletion of the *TP53* locus, were treated or not with doxorubicin. RNA was extracted using the Nucleospin RNAII kit (Macherey Nagel). Libraries were prepared using the NEBNext Ultra Directional RNA Library Kit for Illumina (NEB, Ipswich, USA) and NGS sequencing of the libraries was performed on an Illumina NextSeq500 (Illumina, San Diego, USA) using 2×75 bp sequencing to generate 50M read pairs on average per sample. Experiments were performed in triplicates. Bioinformatic analysis was carried out using an in-house automated pipeline AURIGA that uses the STAR V2.5.3a tool for alignment, FeatureCounts tool V1.5.2 for read counting and DESeq2 V1.18.1 for statistical analysis.

Selection of biomarkers indicative of p53-transcriptional activity

New biomarkers were selected among the transcripts strongly up-regulated by doxorubicin in control cells but not in the cells harbouring heterozygous *TP53* alterations: *CEP170B* (NM_015005), *PODXL* (MIM*602632, NM_001018111), *RRAD* (MIM*179503, NM_004165), *GLS2* (MIM*606365, NM_013267), *CABYR* (MIM*612135, NM_012189), *TP53I3* (MIM*605171, NM_004881), *EPS8L2* (MIM*614988, NM_022772), *SULF2* (MIM*610013, NM_001161841), *SEN1* (MIM*606103, NM_014454) and *FHL2* (MIM*602633, NM_201555). Three control transcripts with a steady expression across all conditions and genotypes and expressed at the same level as the selected targets were also selected: *TBP* (MIM*600075, NM_003194), *RIC8B* (MIM*609147, NM_001330145) and *MPP5* (MIM*606958, NM_022474.3). An internal control of treatment efficacy was included: *PLK1* (MIM*602098, NM_005030.5), whose transcript is downregulated by doxorubicin treatment both in wild-type and mutant cells.

Reverse transcription–quantitative multiplex PCR of short fluorescent fragment (RT-QMPSF)

Reverse transcription (RT) was performed on 100 ng of total RNA using the Verso cDNA Synthesis Kit (Thermo Scientific, Waltham, USA). RT-QMPSF was performed on 1.5 μL of RT using Diamond Taq DNA polymerase (Kaneka Eurogentec, Seraing, Belgium), 6% Dymethyl sulfoxide and 26 PCR cycles (94°C: 30 s/58°C: 1 min/72°C: 30 s). Primer sequences are listed in online supplemental table 1. Amplicons were analysed on an ABI Prism 3500 Genetic Analyzer (Applied Biosystems, Foster City, California, USA) using GeneScan 3.7 software.

Reverse transcription–multiplex ligation probe amplification (RT-MLPA)

RT-MLPA probes were pooled at a concentration of 1 fmol/ μ L each in 10 mM Tris/1 mM EDTA. Probe sequences are given in online supplemental table 1. RT (6.5 μ L), probe mixture (1.5 μ L) and SALSA-MLPA buffer (1.5 μ L, MRC-Holland, Amsterdam, The Netherlands) were mixed before denaturation (95°C, 2 min) and hybridisation (60°C, 1 hour). Ligation was performed at 54°C for 15 min, adding 32 μ L of ligation mixture, and heated 5 min at 98°C. Then, 2.5 μ L of the ligation was added to 7.5 μ L of a Q5 Hot Start High-Fidelity 2X Master Mix (NEB) supplemented with universal fluorescent PCR primers. PCR was performed using 35 cycles (94°C: 30 s/58°C: 30 s/72°C: 30 s). Amplicons were analysed on an ABI Prism 3500 Genetic Analyzer using GeneScan V.3.7 software.

Calculation of p53 functionality score and p53 mRNA ratio

The RT-MLPA or RT-QMPFS profiles of doxorubicin-treated and untreated cells were superimposed after adjusting the control amplicons to the same height. In the treated condition, the peak height of each of the 10 p53 target genes was measured and divided by the sum of the heights of the three control genes. This value was then divided by the same ratio calculated in the untreated condition. In the assay, the mean of the 10 values defines the p53 functionality score. The final p53 functionality score is the mean of the scores obtained in RT-MLPA and RT-QMPFS assays. The p53 mRNA levels were expressed as a ratio of the normal values obtained for 3 *TP53* wild-type control individuals. The efficacy of the genotoxic treatment was assessed by calculating a *PLK1* (MIM*602098) ratio (treated/untreated) normalised with the three controls, which should be less than 0.5.

RESULTS

Development of a rapid p53 functional assay performed on blood

The rationale of the assay is that p53 acts as a powerful transcriptional inductor when DNA damage occurs and that the common deleterious impact of pathogenic variants is the alteration of this transcriptional activity.²⁶ To develop a functional assay directly performed on patient's fresh blood, we first optimised the quantitative assay that we had previously developed in EBV-immortalised cell lines.^{27–28} To this aim, we performed a new comparative transcriptomic analysis using RNA-Seq, including non-polyadenylated RNAs. Four control EBV cell lines wild type for *TP53* and four patients with LFS EBV cell lines were compared in the context of genotoxic stress induced by doxorubicin treatment. We selected 10 biomarkers corresponding to p53 targets involved in different biological pathways controlled by p53, such as cell adhesion and migration, cellular response to stress, apoptosis, cytoskeleton organisation, glycolysis or regulation of other metabolic pathways. To normalise the results, we selected three transcripts with a steady expression across all conditions and genotypes. All these biomarkers were then included in two quantitative assays based on RT-MLPA and RT-QMPFS. To detect in the same assay the potential effect of variants on the *TP53* transcript levels, we added different amplicons or probes corresponding to *TP53* cDNA. As a defect in treatment efficacy would result in a low functionality score leading to the misinterpretation of a wild-type genotype as a mutant one, we also integrated in the assays an internal control of treatment efficacy. After exposure to doxorubicin, cells were harvested and the RT-MLPA and RT-QMPFS assays were

performed in parallel for each sample to increase the robustness of the assay. An arbitrary functionality score was calculated from the induction score of the 10 p53 targets; the p53 RNA levels were evaluated and expressed as a percentage of the mean levels obtained for three wild-type *TP53* individuals. This new quantitative assay, based on both RT-QMPFS and RT-MLPA, was first validated on 31 lymphoblastoid cell lines derived from patients with LFS harbouring different germline heterozygous *TP53* variants (online supplemental table 2).

We then set up the conditions allowing the assay to be performed directly on the patients' peripheral blood. Blood was collected in conventional EDTA tubes and kept at room temperature for 2 days to mimic sample shipping delays. PBMCs were isolated and cultured for 48 hours in a lymphocyte activating medium. Under these conditions, a strong p53 transcriptional response could be monitored in wild-type individuals (figure 1), indicating that testing p53 function directly on patients' blood cells was feasible.

p53 functional analysis of patient's blood cells with different *TP53* genotypes

We then applied the p53 functional assay on blood samples sent to our laboratory for *TP53* molecular analysis (NGS screening of the 11 exons complemented by QMPFS). Molecular and functional analyses were performed in parallel, in double blind conditions. We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic *TP53* variant or to relatives of index cases harbouring *TP53* variants. This sample reflects the real-life recruitment of our diagnostic laboratory as it includes unaffected individuals as well as individuals affected by cancer who may have undergone different chemotherapy treatments. Molecular analyses revealed that 51 individuals had no detectable germline *TP53* variant. For these 51 individuals, the mean p53 functionality score measured was 12.7 (13.6 for the RT-QMPFS assay and 11.9 for the RT-MLPA assay) with a range of 7.5–22.8 (online supplemental table 3 and figure 2). The mean observed p53 mRNA levels were 93% with a range of 74%–125% (online supplemental table 3). In eight tested individuals, molecular analysis revealed seven distinct *TP53* variants which could be considered as likely pathogenic or pathogenic based on their ClinVar classification or their truncating nature (table 1). All the variants tested were confirmed to be germline heterozygous variants. For these eight patients, the assay yielded a reduced score compared with the wild-type individuals (mean 4.8, range 3.1–7.1; table 1 and figure 2). In the patients with missense variants, p53 mRNA levels were above 75%. In contrast, p53 mRNA was clearly reduced in patients harbouring frameshift or splice variants (mean 58%, table 1 and figure 2) probably reflecting the activity of the nonsense-mediated mRNA decay.

Functional evaluation of *TP53* variants of unknown biological significance

Based on these results, we refined the experimental thresholds for the analysis of unclassified variants. A functionality score above 7.5 was considered as indicative of a wild-type *TP53* genotype, a score below 7.5 indicative of a variant impacting p53 function. A score below 5.5 is associated with a strong impact, and a score between 5.5 and 7.5 is associated with an intermediate effect. A reduction in p53 mRNA levels (<65%) was, by itself, suggestive of a defect independently of the functional score obtained. Using these criteria, we undertook the functional interpretation

of 14 rare *TP53* variants which remained unclassified despite the available tools (table 1). These variants included 10 rare missense variants (p.(Pro72His), p.(Gly105Asp), p.(Arg110His), p.(Phe134Leu), p.(Arg158Cys), p.(Pro191Arg), p.(Pro278Arg), p.(Arg283Cys), p.(Leu348Ser), p.(Asp352Tyr)), 2 in-frame deletions (p.(Asn131del), p.(Leu265del)), 1 in-frame deletion–insertion [p.(Gly108_Phe109delinsVal)] and 1 rare variant within the 5'UTR region (c.-117G>T). For these rare variants (table 1), except p.(Pro191Arg) and c.-117G>T, the functional score was below 7.5, classifying these variants as 'functionally abnormal', according to the terminology recently recommended for the functional assays.²⁹ The p.(Pro72His) variant, which affects the same amino acid as the common p.(Pro72Arg) PEX4 polymorphism (rs1042522), yielded a score of 6.1 with no detectable effect on

p53 mRNA, suggesting that it has a moderate effect on p53 function. For this patient, an EBV-cell line was established, and the functional assay performed on the cell line yielded comparable results with a reduced score of 7.5 (normal score in EBV>10) and no impact on p53 mRNA levels. The p.(Pro191Arg) variant and the c.-117G>T variant had no detectable impact on the transcriptional activity, which led us to consider them as functionally normal.

Functional impact of the *TP53* c.*1175A>C polymorphism located within the polyadenylation signal

We performed the assay in the unaffected mother (individual 76, table 1 and online supplemental table 3) of a young female

Figure 1 P53 functional assay on peripheral blood. (A) Schematic representation of the blood p53 functional assay workflow. (B,C) Typical RT-QMPSF (B) and RT-MLPA (C) results obtained for individual 15 with a wild-type *TP53* genotype. The fluorescent profiles of doxorubicin-treated cells (red line) and untreated cells (blue line) were superimposed using the three control amplicons (*RIC8B*, *TBP* and *MPP5*). The horizontal bars indicate for each p53 target gene the level of expression in untreated cells. Treatment efficacy was evaluated by the transcriptional repression of the *PLK1* marker (Plk1 treated/untreated ratio below 0.5). In the treated condition, the peak height of each of the 10 p53 target genes was measured and divided by the sum of the heights of the three control genes. This value was divided by the same ratio calculated in the untreated condition to yield an arbitrary p53 functionality score. The p53 mRNA levels were expressed as a ratio of the normal values obtained for three control individuals. PBMC, peripheral blood mononuclear cell; RT-MLPA, reverse transcription–multiplex ligation probe amplification; RT-QMPSF, reverse transcription–quantitative multiplex PCR of short fluorescent fragment.

Figure 2 p53 functional scores and mRNA level ratios in individuals with wild-type *TP53* or with germline *TP53* variants. (A) p53 functionality scores obtained in 51 wild-type *TP53* individuals, compared with the scores obtained for nine samples from eight individuals carrying a classified *TP53* variant (online supplemental table 3) using a Mann-Whitney non-parametric test. (B) Comparison of the p53 mRNA ratios obtained in 51 wild-type *TP53* individuals and in samples carrying a missense (five samples) or a truncating variant of *TP53* (four samples), using a Kruskal-Wallis test with Dunns post-test ($p=0.0031$). *** $P<0.01$.

patient (individual 77, online supplemental table 3) who developed a high-grade glioma at 5 years of age and who carried a frameshift *TP53* variant [c.723del, p.(Cys242Alafs*5)], transmitted by her father (individual 58, table 1 and online supplemental table 3). Unexpectedly, the mother had a reduced score of 5.5 and a moderate decrease in p53 mRNA levels (69%). A second blood sample yielded the same results (5.7; 73%). To explore this discrepancy, we reanalysed by NGS the whole *TP53* locus in this family. This analysis revealed that the affected daughter carried the rs78378222 c.*1175A>C variant located within the polyadenylation signal, in addition to the frameshift *TP53* variant. This polymorphic variant, present in 1.7% of non-Finnish Europeans, had previously been shown to be a risk factor for glioma and to impair 3'-end processing of p53 mRNA.^{30–33} Remarkably, the reanalysis of the *TP53* locus in the mother revealed that she was homozygous for the c.*1175A>C variant. The p53 functional score in the index case harbouring the p.(Cys242Alafs*5) variant and the c.*1175A>C polymorphism (individual 77, online supplemental table 3) was lower than that obtained in her father harbouring only the frameshift variant (3.1 vs 7.1 and 6.0; see table 1 and online supplemental table 3). We analysed the impact of the c.*1175A>C variant on p53 mRNA 3'-end processing using a dedicated RT-QMPSF with two amplicons located upstream and downstream of the polyadenylation site ('exon 11' and 'postpoly-A' respectively). This analysis revealed a reduction in p53 normal transcripts and the appearance of longer transcripts in the mother's and daughter's blood cells (figure 3).

DISCUSSION

The interpretation of germline *TP53* variants in patients with cancer is critical and should be performed before starting treatment considering their medical impact. The main objective of our assay was to provide a fast functional classification of rare uncharacterised variants in order to help clinicians with decision-making. Compared with the previous assay that we developed in EBV-immortalised lymphocytes,^{27–28} this blood assay does not require long-term cell culture and the results can be obtained within 1 week, fulfilling the timing required for diagnostic practice. The only constraint is to perform it within 48 hours after

blood sampling in order to obtain robust results. Under these conditions, we were able to successfully analyse samples sent from other European countries.

Our assay fulfils most of the recommendations recently published by the Clinical Genome Resource Sequence Variant Interpretation working group regarding the clinical validity of functional assays²⁹: (1) compared with the previously described p53 functional assays that test in vitro either cloned cDNA in yeast or artificial mutant libraries in cancer cell lines,^{23–25} this blood assay is performed in clinical samples in the patients' genetic context; (2) the assay evaluates the transcriptional activity of p53 and not a specific domain of the protein; (3) it analyses simultaneously the impact of the variant on protein function and mRNA levels; (4) it was validated using 51 wild-type *TP53* controls and 8 patients with seven distinct pathogenic or likely-pathogenic *TP53* variants; and finally, (5) results show the robustness of the assay. Indeed, as shown in table 1, for 12 tested variants, we were able to perform the assay on EBV-immortalised cell lines and the results were very similar. Moreover, for five individuals, two different blood samples were tested and yielded similar results (table 1), and two variants (c.844C>T, p.(Arg282Trp); c.847C>T, p.(Arg283Cys)) were tested on two different individuals' blood with concordant results (4.8 vs 5.0 and 5.3 vs 6.4).

We observed among the wild-type *TP53* individuals a wide range of functionality scores (7.5–22.8). This probably suggests that there is a variability of the p53-mediated transcriptional response to DNA damage in the general population, although no obvious impact of age, clinical status or sex could be observed. The thresholds used in this study could be refined by testing additional deleterious variants. Despite this variability, all pathogenic/likely pathogenic variants generated low p53 functionality scores, and variants resulting in premature stop codons were also detected by a clear reduction of p53 mRNA levels. In addition, our assay allows testing of non-missense variants such as in frame indels. It should be highlighted that none of the previously published functional assays can be considered as a gold-standard method to classify germline *TP53* variants.^{23–25} Therefore, no available p53 functional assay can be used to calibrate the blood assay. Indeed,

Table 1 Interpretation of germline *TP53* variants integrating the blood p53 functional assay

Variant*	Bioinformatic predictions‡				Functional status of the variants assessed in yeast and human cancer cell lines				ClinVar Classification§	Blood p53 functional assay¶ in p53 score, mRNA%	p53 functional assay in EBV cell lines score, mRNA%	Interpretation according to the assay
	MAF†	Align GVGD	PolyPhen -2	SIFT	Bayes Del	Kato assay**	Kotler assay††	Giacomelli assay‡‡				
Pathogenic/likely pathogenic variants												
c.524G>A p.(Arg175His)	0.000004	C25	P	D	0.5462	Non-functional	Non-functional	LOF DNE	Pathogenic	Ind. 52: 3.2; 96%	2.9; 93% 4.1; 86%	Functionally abnormal
c.542G>A p.(Arg181His)	0.000014	C25	D	D	0.2584	Partially functional	Functional	Unclassified	Pathogenic/likely pathogenic	Ind. 53: 3.8; 81%		Functionally abnormal
c.844C>T p.(Arg282Trp)	0.000004	C65	D	D	0.5418	Non-functional	Non-functional	LOF DNE	Pathogenic/likely pathogenic	Ind. 54: 4.8; 102% Ind. 55: 5.0; 98%	2.0; 104% 2.7; 116% 4.6; 76%	Functionally abnormal
c.1010G>A p.(Arg337His)	0.000012	C25	D	D	0.1777	Partially functional	NA	Not LOF Not DNE	Pathogenic	Ind. 56: 5.4; 101%	5.8; 81% 6.0; 85% 6.5; 81% 6.9; 101%	Functionally abnormal
c.375G>A p.? Splicing Alteration	NR	/	/	/	/	/	Functional	NA	Pathogenic	Ind. 57: 3.1; 61%	5.5; 61%§§	Functionally abnormal
c.723del p.(Cys242Alafs*5)	NR	/	/	/	/	NA	NA	NA	NR	Ind. 58: 51.7; 56% 52: 6.0; 52%	4.2; 52%§§	Functionally abnormal
c.770del p.(Leu257Argfs*88)	NR	/	/	/	/	NA	Non-functional	NA	NR	Ind. 59: 4.7; 62%		Functionally abnormal
Benign variant												
c.704A>G p.(Asn235Ser)	0.01945	C0	B	T	-0.0342	Functional	Functional	Not LOF Not DNE	Benign	Ind. 60: 12.9; 118%		Functionally normal
Unclassified rare variants												
c.215C>A p.(Pro72His)	NR	C0	P	D	-0.1017	Functional	NA	Not LOF Not DNE	Uncertain significance	Ind. 61: 6.1; 86%	7.5; 107%§§	Functionally abnormal
c.314G>A p.(Gly105Asp)	NR	C65	D	D	0.5683	Partially functional	Functional	LOF DNE	Conflict, int: Likely pathogenic/uncertain significance	Ind. 62: 2.9; 82%	2.1; 85% 3.6; 70%	Functionally abnormal
c.329G>A p.(Arg110His)	0.000046	C0	B	T	0.0728	Partially functional	Functional	Not LOF Not DNE	Uncertain significance	Ind. 63: 4.1; 83%	3.7; 92% 4.7; 91%§§ 5.2; 94%	Functionally abnormal
c.402T>G p.(Phe134Leu)	NR	C0	D	D	0.3166	Non-functional	Non-functional	LOF DNE	NR	Ind. 64: 3.5; 78%	3.5; 94%§§	Functionally abnormal
c.472C>T p.(Arg158Cys)	0.000008	C65	D	D	0.5145	Partially functional	Functional	Unclassified	Conflict, int: Likely pathogenic/uncertain significance	Ind. 65: 3.2; 86%		Functionally abnormal
Functionally normal												
c.572C>G p.(Pro191Arg)	0.000012	C35	P	D	0.0942	Functional	Functional	Not LOF Not DNE	Uncertain significance	Ind. 66: 17.1; 90%		Functionally normal
c.832C>G p.(Pro278Arg)	NR	C65	D	D	0.6078	Non-functional	Non-functional	LOF DNE	Uncertain significance	Ind. 67: 5.1; 78%	3.9; 108%§§	Functionally abnormal
c.847C>T p.(Arg283Cys)	0.000074	C55	B	D	0.3309	Functional	Functional	Not LOF Not DNE	Uncertain significance	Ind. 68: 5.3; 79% Ind. 69: 6.4; 88%	3.1; 96% 2.5; 89%§§ 5.6; 86% 5.4; 88%	Functionally abnormal
Functionally abnormal												
c.1043T>C p.(Leu348Ser)	NR	C65	D	D	0.5439	Non-functional	NA	Not LOF Not DNE	NR	Ind. 70: 51.5; 89% 52: 6.1; 90%		Functionally abnormal
c.1054G>T p.(Asp352Tyr)	NR	C35	D	D	0.0844	Functional	NA	Not LOF Not DNE	Uncertain significance	Ind. 71***: 51.4; 101% 52: 5.0; 106%	2.3; 90%	Functionally abnormal
c.323_325del p.(Gly108_Phe109delinsVal)	NR	/	/	/	/	/	/	/	NR	Ind. 72: 3.8; 94%		Functionally abnormal

Continued

Table 1 Continued

Variant*	Bioinformatic predictions‡				Functional status of the variants assessed in yeast and human cancer cell lines				ClinVar classification§	Blood p53 functional assay¶ in p53 score, mRNA%	p53 functional assay in EBV cell lines score, mRNA%	Interpretation according to the assay
	MAF†	Align GVG	PolyPhen-2	SIFT	Bayes Del	Kato assay**	Kotler assay††	Giacomelli assay‡‡				
c.393_395del p.(Asn131del)	NR	/	/	/	/	NA	Non-functional	NA	Uncertain significance	Ind. 73: 51:2.6; 80% 52:4.8; 95%		Functionally abnormal
c.792_794del p.(Leu265del)	NR	/	/	/	/	/	NA	NA	NR	Ind. 74: 3.4; 95%		Functionally abnormal
c.117G>T p.(=) (5'UTR)	NR	/	/	/	/	NA	NA	NA	NR	Ind. 75: 20.5; 100%		Functionally normal
Polymorphism												
c.*1175A>C p.(=) (Homozygous)	0.01189	/	/	/	/	NA	NA	NA	Conflict: int: likely benign/uncertain significance	Ind. 76: 51:5.5; 69% 52:5.7; 73%		Functionally abnormal when homozygous

*Described according to the reference transcript NM_000546.5.

†Allele frequency in the general population, as indicated in gnomAD (<https://gnomad.broadinstitute.org/>).‡ClinVar classification of the variant impact on protein, according to the Align GVG (C0: tolerated; other classes: Damaging), PolyPhen-2 (D: probably damaging, P: possibly damaging, B: benign), SIFT (D: Damaging, T: tolerated) and BayesDel (score<0.16: tolerated, as indicated in Fontana et al, 2018²⁰) algorithms.§The variant classification of the variant impact on protein, according to the Align GVG (C0: tolerated; other classes: Damaging), PolyPhen-2 (D: probably damaging, P: possibly damaging, B: benign), SIFT (D: Damaging, T: tolerated) and BayesDel (score<0.16: tolerated, as indicated in Fontana et al, 2018²⁰) algorithms.¶The variant classification of the variant impact on protein, according to the Align GVG (C0: tolerated; other classes: Damaging), PolyPhen-2 (D: probably damaging, P: possibly damaging, B: benign), SIFT (D: Damaging, T: tolerated) and BayesDel (score<0.16: tolerated, as indicated in Fontana et al, 2018²⁰) algorithms.**As determined in the assay developed by Kotler et al¹⁸ and based on the quantification of the antiproliferative activity of the variant in the p53-null H1299 cancer cell line.††As determined in the assay developed by Giacometti et al¹⁹ and based on the quantification of the antiproliferative activity of the variant in the p53-null A459 cell line after exposure to high doses of etoposide DNA breaking agents and to induce in p53-wild-type A459 cell line resistance to Nutlin-3.

‡‡Conflicting interpretations of pathogenicity.

§§For this individual, a second TP53 variation was identified in chr. 7:10211>A, p.(Phe314Ile), which is classified as benign.

¶¶DNE, dominant negative effect; LOE, loss of function; NR, not reported; RT-MPA, reverse transcription-multiplex ligation probe amplification; RT-QMPSE, reverse transcription-quantitative multiplex PCR of short fluorescent fragment.

as illustrated in table 1, discordant results were obtained for variants unambiguously classified in ClinVar as pathogenic or likely pathogenic. In particular, the founder Brazilian p.(Arg337His), an example of a variant with low penetrance, highlights the limits of the available tools. Whereas segregation data performed on large Brazilian pedigrees have clearly shown that this variant is pathogenic,³⁴ bioinformatic predictions and functional analyses³⁵ are conflicting (table 1). Our blood functional assay clearly shows that this variant alters the transcriptional activity of p53, although to a lesser extent than DNE missense variations, highlighting the limits of functional assays based on overexpression of cDNA. This result was confirmed in four additional patients carrying this variant using EBV cell lines (table 1).

The blood functional assay performed on PBMC harbouring unclassified variants led us to consider 12 variants (p.(Pro72His), p.(Gly105Asp), p.(Arg110His), p.(Phe134Leu), p.(Arg158Cys), p.(Pro278Arg), p.(Arg283Cys), p.(Leu348Ser), p.(Asp352Tyr), p.(Gly108_Phe109delinsVal), p.(Asn131del), p.(Leu265del)) as 'functionally abnormal', some with high impact. The interpretation is particularly challenging for p.(Pro72His), p.(Arg110His), p.(Arg158Cys), p.(Arg283Cys) and p.(Asp352Tyr) variants, as they were considered in yeast assays as functional or partially functional, and the Giacometti assay classified them as not LOF_not DNE or was not conclusive. The low functionality score observed for p.(Arg110His) was confirmed in an EBV cell line derived from the patient and confirmed in two EBV cell lines from other patients carrying this variant. The result for the p.(Asp352Tyr) variant was confirmed on a second blood sample and with an EBV cell line derived from another patient also carrying this variant. The effect of p.(Arg283Cys) was also confirmed in EBV cell lines derived from the patient and from three additional patients with the same variant (table 1).

The clinical utility of the p53 functional assay is highlighted by the p.(Pro191Arg) variant. This variant was initially detected in a child with medulloblastoma at 2 years of age and whose brother died from a fibrosarcoma. Presymptomatic testing revealed that an unaffected brother (18 months), the mother and two maternal aunts were also carriers. We were then requested to evaluate this variant, and the functional assay performed in the maternal aunt (individual 65, online supplemental table 3) clearly showed that this variant does not alter the p53 transcriptional activity (table 1 and online supplemental table 3). Considering this result, segregation analysis was performed on the brother's fibrosarcoma sample, revealing the absence of the variant and consolidating the conclusion of a non-pathogenic variant.

Our results show that this blood functional assay is also able to detect TP53 variations outside the coding regions, which are the only regions commonly analysed. Thanks to this assay, we discovered that the unaffected mother of an index case was homozygous for the polymorphic c.*1175A>C variant, and we show that this variant decreases p53 mRNA by altering the polyadenylation signal and produces longer transcripts extending beyond the poly-A site, as previously reported.³⁰ When present on both alleles, this variant impacts p53 functionality with the same magnitude as a germline pathogenic TP53 variant. This prompted us to recommend breast MRI every year for this unaffected adult relative. We had the opportunity to perform the assay on EBV-immortalised lymphocytes harbouring only this heterozygous variant, and we observed a normal score (data not shown), suggesting that the heterozygous c.*1175A>C variant alone is insufficient to alter p53 function. The comparison of the p53 functional scores observed

Figure 3 Impact of the heterozygous and homozygous *TP53* c.*1175A>C variation on p53 pre-mRNA 3' end processing. (A) Schematic representation of the *TP53* 3' end region. The c.*1175A>C variant is predicted to yield at least two different transcripts; the upper one corresponds to the normal transcript with pre-mRNA cleavage and polyadenylation, and the lower one to longer transcript that extends after the poly-A signal. 'Exon 11' primers amplify both transcripts, while 'postpoly-A' primers specifically amplify the longer transcripts. As postpoly-A primers could also amplify gDNA, primers 'exon 7' and 'exon 10', which are specific to gDNA, were added to the reaction in order to monitor DNA contamination. (B) RT-QMPSF result obtained for the index case's father (individual 58, S1; table 1 and online supplemental table 3) carrying the variant *TP53* c.723del, p.(Cys242Alafs*5). The profile (in red) was superimposed on the profile of a control individual wild type for *TP53* (in blue), using the control amplicons *RIC8B* and *TBP*. (C) RT-QMPSF result obtained for the index case's mother (individual 76, S1; table 1 and online supplemental table 3) carrying the c.*1175A>C variant at the homozygous state. (D) RT-QMPSF result for the index case (individual 77, online supplemental table 3) carrying the c.723del, p.(Cys242Alafs*5) variant and the c.*1175A>C in trans. Red arrows indicate the appearance of longer p53 transcripts. The horizontal bars show the reduction of the normal p53 transcript level, as compared with the control. RT-QMPSF, reverse transcription–quantitative multiplex PCR of short fluorescent fragment.

in the index case who developed a high-grade glioma at 5 years of age and harbours the null c.723del, p.(Cys242Alafs*5) variant and in trans the polymorphic c.*1175A>C variant, and in her father carrying only the *TP53* null variant suggests

that the c.*1175A>C variant may act as a genetic modifier in pathogenic *TP53* variant carriers and could increase the risk of glioma in carriers, as previously shown in the general population.^{30–33}

In summary, we suggest that our blood p53 functional assay should be a useful tool not only for the rapid interpretation of germline *TP53* variants of unknown significance in clinical practice, in complement to the previously developed assays, but also for the indirect detection of cryptic alterations within regulatory regions impacting p53 function.

Acknowledgements The authors are grateful to their French and European colleagues for providing clinical information and sending blood samples for TP53 analysis. The authors are indebted to Philippe Ruminy (Inserm U1245, Comprehensive Cancer Centre Becquerel, Rouen) for advices on the reverse transcription–multiplex ligation probe amplification experiments and to Nikki Sabourin-Gibbs (Rouen University Hospital) for her assistance in editing the manuscript.

Contributors IT, GB and TF formulated research goals and aims. Functional analyses were performed by SR and MR. RNA-Seq was performed by SR, CD and IT and bioinformatic analysis by RL and SC. Molecular analyses were performed by JB, EB, FC, GL, SV and supervised by GB, EK and SBD. TF, IT and GB supervised the overall progress and manuscript writing. SR and MR contributed equally to this work.

Funding This work was supported by the North-West Canceropole, the European Regional Development Fund (European Union and Région Normandie), the Association pour la Recherche contre le Cancer and the Ligue Contre le Cancer.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. Deidentified participant data are available from thierry.frebouurg@chu-rouen.fr.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Isabelle Tournier <http://orcid.org/0000-0002-5544-048X>

REFERENCES

- 1 Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheimer R, Evans DG, European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. *Eur J Hum Genet* 2020. doi:10.1038/s41431-020-0638-4. [Epub ahead of print: 26 May 2020].
- 2 Bougeard G, Renaux-Petel M, Flaman J-M, Charbonnier C, Fery P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugières L, Caron O, Benusiglio PR, Bressac-de Paillerets B, Bonadona V, Bonaïti-Pellié C, Tinat J, Baert-Desurmont S, Frebourg T. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. *J Clin Oncol* 2015;33:2345–52.
- 3 Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, Bremer RC, Rosenberg PS, Savage SA. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. *Cancer* 2016;122:3673–81.
- 4 Kasper E, Angot E, Colasse E, Nicol L, Sabourin J-C, Adriouch S, Lacoume Y, Charbonnier C, Raad S, Frebourg T, Flaman J-M, Bougeard G. Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations. *Eur J Cancer* 2018;101:254–62.
- 5 Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, Gallinger B, Naumer A, Kohlmann W, Novokmet A, Tabori U, Tijerim M, Greer M-LC, Finlay JL, Schiffman JD, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. *Lancet Oncol* 2016;17:1295–305.
- 6 Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer M-LC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, Mullighan CG, Onel K, Pajtker JW, Pfister SM, Savage SA, Schiffman JD, Schneider KA, Strong LC, Evans DGR, Wasserman JD, Villani A, Malkin D. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. *Clin Cancer Res* 2017;23:e38–45.
- 7 Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, Garber J, O'Neill AF, Eeles RA, Evans DG, Bleiker E, Sonke GS, Ruijs M, Loo C, Schiffman J, Naumer A, Kohlmann W, Strong LC, Bojadziewa J, Malkin D, Rednam SP, Stoffel EM, Koeppe E, Weitzel JN, Slavin TP, Nehoray B, Robson M, Walsh M, Manelli L, Villani A, Thomas DM, Savage SA. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. *JAMA Oncol* 2017;3:1634–9.
- 8 Caron O, Frebourg T, Benusiglio PR, Foulon S, Brugières L. Lung adenocarcinoma as part of the Li-Fraumeni syndrome spectrum: preliminary data of the LIFSCREEN randomized clinical trial. *JAMA Oncol* 2017;3:1736–7.
- 9 Ruijs MWG, Loo CE, van Buchem CAJM, Bleiker EMA, Sonke GS. Surveillance of Dutch patients with Li-Fraumeni syndrome: the Life-Guard study. *JAMA Oncol* 2017;3:1733–4.
- 10 Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J, Benaffif S, Dias A, Mikropoulos C, Pope J, Chamberlain A, Gunapala R, Izatt L, Side L, Walker L, Tomkins S, Cook J, Barwell J, Wiles V, Limb L, Eccles D, Leach MO, Shanley S, Gilbert FJ, Hanson H, Gallagher D, Rajashanker B, Whitehouse RW, Koh D-M, Sohaib SA, Evans DG, Eeles RA, SIGNIFY Study Steering Committee. Baseline results from the UK signify study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. *Fam Cancer* 2017;16:433–40.
- 11 Bojadziewa J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni syndrome education and early detection (lead) clinic. *Fam Cancer* 2018;17:287–94.
- 12 O'Neill AF, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, Masciari S, Parker E, Barreto M, London WB, Garber JE, Diller L. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: a single institution pilot study. *Pediatr Blood Cancer* 2018;65. doi:10.1002/pbc.26822. [Epub ahead of print: 27 Oct 2017].
- 13 Paixão D, Guimarães MD, de Andrade KC, Nóbrega AF, Chojniak R, Achatz MI. Whole-Body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients. *Cancer Imaging* 2018;18.
- 14 Bancroft EK, Saya S, Brown E, Thomas S, Taylor N, Rothwell J, Pope J, Chamberlain A, Page E, Benaffif S, Hanson H, Dias A, Mikropoulos C, Izatt L, Side L, Walker L, Donaldson A, Cook JA, Barwell J, Wiles V, Limb L, Eccles DM, Leach MO, Shanley S, Gilbert FJ, Gallagher D, Rajashanker B, Whitehouse RW, Koh D-M, Sohaib SA, Evans DG, Eeles RA, Walker LG. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY). *J Med Genet* 2020;57:226–36.
- 15 Li FP, Fraumeni JF. Soft-Tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? *Ann Intern Med* 1969;71:747–52.
- 16 Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Nelson CE, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233–8.
- 17 Srivastava S, Zou ZQ, Pirolo K, Blattner W, Chang EH. Germ-Line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. *Nature* 1990;348:747–9.
- 18 Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. *J Clin Oncol* 2009;27:1250–6.
- 19 Ruijs MWG, Verhoef S, Rookus MA, Prunel R, van der Hout AH, Hogervorst FBL, Kluijff I, Sijmons RH, Aalfs CM, Wagner A, Ausems MGEM, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van 't Veer LJ. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. *J Med Genet* 2010;47:421–8.
- 20 Fortunato C, James PA, Young EL, Feng B, Olivier M, Pesaran T, Tavtigian SV, Spurdle AB. Improved, ACMG-compliant, in silico prediction of pathogenicity for missense substitutions encoded by TP53 variants. *Hum Mutat* 2018;39:1061–9.
- 21 Fortunato C, Cipponi A, Ballinger ML, Tavtigian SV, Olivier M, Ruparel V, Haupt Y, Haupt S, Study ISK, Tucker K, Spurdle AB, Thomas DM, James PA. A quantitative model to predict pathogenicity of missense variants in the TP53 gene. *Hum Mutat* 2019;40:788–800.
- 22 ClinGen. TP53-specific ACMG/AMP guidelines. Available: https://clinicalgenome.org/site/assets/files/3876/clinngen_tp53_acmg_specifications_v1.pdf
- 23 Kato S, Han S-Y, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. *Proc Natl Acad Sci U S A* 2003;100:8424–9.
- 24 Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A, Hopf TA, Marks DS, Oren M, Segal E. A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. *Mol Cell* 2018;71:178–90.
- 25 Giacomelli AO, Yang X, Lintner RE, McFarland JM, Doby M, Kim J, Howard TP, Takeda DY, Ly SH, Kim E, Gannon HS, Hurlburt B, Sharpe T, Goodale A, Fritchman B, Steelman S, Vazquez F, Tsherniak A, Aguirre AJ, Doench JG, Piccioni F, Roberts CWM, Meyerson M, Getz G, Johannessen CM, Root DE, Hahn WC. Mutational processes shape the landscape of TP53 mutations in human cancer. *Nat Genet* 2018;50:1381–7.
- 26 Hafner A, Bulky ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. *Nat Rev Mol Cell Biol* 2019;20:199–210.

- 27 Zerdoumi Y, Aury-Landas J, Bonaïti-Pellié C, Derambure C, Sesboué R, Renaux-Petel M, Frebourg T, Bougeard G, Flaman J-M. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients. *Hum Mutat* 2013;34:453–61.
- 28 Zerdoumi Y, Lanos R, Raad S, Flaman J-M, Bougeard G, Frebourg T, Tournier I. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. *Hum Mol Genet* 2017;26:2591–602.
- 29 Brnich SE, Abou Tayoun AN, Couch FJ, Cutting GR, Greenblatt MS, Heinen CD, Kanavy DM, Luo X, McNulty SM, Starita LM, Tavtigian SV, Wright MW, Harrison SM, Biesecker LG, Berg JS, Clinical Genome Resource Sequence Variant Interpretation Working Group. Recommendations for application of the functional evidence P53/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. *Genome Med* 2019;12:3.
- 30 Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Nexø BA, Tjønneland A, Overvad K, Rudnai P, Gurzau E, Koppova K, Hemminki K, Corredera C, Fuentelsaz V, Grasa P, Navarrete S, Fuertes F, García-Prats MD, Sanambrosio E, Panadero A, De Juan A, García A, Rivera F, Planelles D, Soriano V, Requena C, Aben KK, van Rossum MM, Cremers RGHM, van Oort IM, van Spronsen D-J, Schalken JA, Peters WHM, Helfand BT, Donovan JL, Hamdy FC, Badescu D, Codreanu O, Jinga M, Csiki IE, Constantinescu V, Badea P, Mates IN, Dinu DE, Constantin A, Mates D, Kristjansdottir S, Agnarsson BA, Jonsson E, Barkardottir RB, Einarsson GV, Sigurdsson F, Møller PH, Stefansson T, Valdimarsson T, Johannsson OT, Sigurdsson H, Jonsson T, Jonasson JG, Tryggvadottir L, Rice T, Hansen HM, Xiao Y, Lachance DH, O'Neill BP, Kosel ML, Decker PA, Thorleifsson G, Johannsdottir H, Helgadottir HT, Sigurdsson A, Steinthorsdottir V, Lindblom A, Sandler RS, Keku TO, Banasik K, Jørgensen T, Witte DR, Hansen T, Pedersen O, Jinga V, Neal DE, Catalona WJ, Wrensch M, Wiencke J, Jenkins RB, Nagore E, Vogel U, Kiemeny LA, Kumar R, Mayordomo JL, Olafsson JH, Kong A, Thorsteinsdottir U, Rafnar T, Stefansson K, Swedish Low-risk Colorectal Cancer Study Group. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. *Nat Genet* 2011;43:1098–103.
- 31 Egan KM, Nabors LB, Olson JJ, Monteiro AN, Browning JE, Madden MH, Thompson RC. Rare TP53 genetic variant associated with glioma risk and outcome. *J Med Genet* 2012;49:420–1.
- 32 Enciso-Mora V, Hosking FJ, Di Stefano AL, Zelenika D, Shete S, Broderick P, Idhah A, Delattre J-Y, Hoang-Xuan K, Marie Y, Labussière M, Alentorn A, Ciccarino P, Rossetto M, Armstrong G, Liu Y, Gousias K, Schramm J, Lau C, Hepworth SJ, Schoemaker M, Strauch K, Müller-Nurasyid M, Schreiber S, Franke A, Moebus S, Eisele L, Swerdlow A, Simon M, Bondy M, Lathrop M, Sanson M, Houlston RS. Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222. *Br J Cancer* 2013;108:2178–85.
- 33 Wang Z, Rajaraman P, Melin BS, Chung CC, Zhang W, McKean-Cowdin R, Michaud D, Yeager M, Ahlborn A, Albanes D, Andersson U, Freeman LEB, Buring JE, Butler MA, Carreón T, Feychting M, Gapstur SM, Gaziano JM, Giles GG, Hallmans G, Henriksson R, Hoffman-Bolton J, Inskip PD, Kitahara CM, Marchand LL, Linet MS, Li S, Peters U, Purdue MP, Rothman N, Ruder AM, Sesso HD, Severi G, Stampfer M, Stevens VL, Viswanathan K, Wang SS, White E, Zeleniuch-Jacquotte A, Hoover R, Fraumeni JF, Chatterjee N, Hartge P, Chanock SJ. Further confirmation of germline glioma risk variant rs78378222 in TP53 and its implication in tumor tissues via integrative analysis of TCGA data. *Hum Mutat* 2015;36:684–8.
- 34 Achatz MW, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, Da Rocha JCC, Vettore AL, Hainaut P. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. *Cancer Lett* 2007;245:96–102.
- 35 Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, Malkin D. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's Oncology Group study. *J Clin Oncol* 2015;33:602–9.